Tvardi Therapeutics
TVRD
163 hedge funds and large institutions have $166M invested in Tvardi Therapeutics in 2023 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 37 increasing their positions, 58 reducing their positions, and 26 closing their positions.
377% more call options, than puts
Call options by funds: $644K | Put options by funds: $135K
15% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 26
2% more funds holding
Funds holding: 160 → 163 (+3)
0.01% less ownership
Funds ownership: 1.76% → 1.75% (-0.01%)
36% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 58
53% less capital invested
Capital invested by funds: $354M → $166M (-$187M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$3.53M |
| 2 |
Squarepoint
New York
|
+$1.82M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.71M |
| 4 |
Two Sigma Investments
New York
|
+$1.52M |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$1.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$4.57M |
| 2 |
ACM
Altium Capital Management
New York
|
-$2.1M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$1.73M |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$1.47M |
| 5 |
BlackRock
New York
|
-$1.21M |
TVRD Hedge Fund Activity: Q1 2023 in Review
163 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q1 2023, worth a combined $166M — down 53% from $354M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new TVRD positions and 26 closed out — a net gain of 4 holders — while 37 added to existing stakes and 58 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $3.53M. The largest seller was Bain Capital Life Sciences Investors, cutting an estimated $4.57M.
- 163 institutional investors held Tvardi Therapeutics (TVRD) as of Q1 2023, up from 160 in Q4 2022.
- Funds reported $166M of Tvardi Therapeutics stock for Q1 2023, down 53% quarter-over-quarter.
- 30 funds opened new Tvardi Therapeutics positions in Q1 2023 and 26 closed out, a net change of +4 holders.
- The largest Tvardi Therapeutics buyer in Q1 2023 was Citadel Advisors, an estimated $3.53M added.
- The largest Tvardi Therapeutics seller in Q1 2023 was Bain Capital Life Sciences Investors, an estimated $4.57M sold.
Based on aggregated 13F filings for Q1 2023.